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Abstract
Due to molecular mimicry, Campylobacter jejuni lipo-oligosaccharides can induce a cross-reactive antibody response to nerve gangliosides,
which leads to Guillain–Barre´ syndrome (GBS). Cross-reactive antibodies to ganglioside GQ1b are strongly associated with oculomotor
weakness in GBS and its variant, Miller Fisher syndrome (MFS). Antigen recognition is a crucial ﬁrst step in the induction of a cross-reactive
antibody response, and it has been shown that GQ1b-like epitopes expressed on the surface of C. jejuni are recognized by sialic acid-binding
immunoglobulin-like lectin-7 (Siglec-7). We aimed to determine the epitope speciﬁcity of C. jejuni binding to Siglec-7, and correlate the
outcome to disease symptoms in GBS and MFS patients. Using a well-deﬁned GBS/MFS-associated C. jejuni strain collection, which included
three sialic acid knockout strains, we found that Siglec-7 exclusively binds to C. jejuni strains that express terminal disialylated ganglioside
mimics. When serological and diagnostic patient records were correlated with the Siglec-7-binding properties, we observed an association
between Siglec-7 binding and the presence of anti-GQ1b antibodies in patient serum. In addition, Siglec-7 binding was associated with
oculomotor weakness in GBS and MFS patients. Lipo-oligosaccharide-speciﬁc binding of C. jejuni to Siglec-7 may be an initiating event in
immune recognition and presentation, and lead to anti-GQ1b antibody production and the development of ocular weakness in GBS or MFS.
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Introduction
Guillain–Barre´ syndrome (GBS) is an antibody-mediated
autoimmune disease of the peripheral nerves, which mainly
arises after gastrointestinal infection [1–3]. GBS is character-
ized by rapidly progressing acute ascending paralysis, which can
result in complete systemic paralysis and the need for artiﬁcial
respiration [4]. Miller Fisher syndrome (MFS) is a restricted
variant of GBS, characterized by paralysis of the eye muscles
(oculomotor weakness), lack of coordination and loss of
tendon reﬂexes, without limb weakness [5]. GBS–MFS overlap
syndrome may also occur in patients who display a combina-
tion of limb and oculomotor weakness [6,7].
Campylobacter jejuni is the predominant infection preceding
the onset ofweakness and paralysis inGBS andMFS [8,9].C. jejuni
strains isolated from GBS patients frequently express lipo-
oligosaccharide (LOS) structures that contain glycan moieties
which mimic gangliosides from the human peripheral nervous
system[10]. In thesepatients and inanimalmodels, theantibodies
raised during the immune response to C. jejuni LOS can cross-
react with various gangliosides and lead to complement-depen-
dent nerve destruction and paralysis [11,12].
Guillain–Barre´ is a syndromic disease entity with a heter-
ogeneous presentation of symptoms [2]. Ganglioside mimicry
in C. jejuni is strongly associated with the speciﬁcity of the
cross-reactive antibody response and the clinical neurological
phenotype. C. jejuni can express monosialylated and disialylated
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LOS with a(2,3)- or a(2,3/2,8)-linked sialic acid residues,
respectively. Monosialylated C. jejuni strains are predominantly
isolated from the stools of patients with GBS. In agreement
with this observation, antibodies against monosialylated struc-
tures, including GM1a, GM1b, GD1a and GalNAc-GD1a, are
frequently detected in the serum of GBS patients [13,14]. In
contrast, C. jejuni strains with disialylated LOS that mimic
GQ1b-like epitopes including GD1c and GD3 are closely
associated with MFS patients, who often have cross-reactive
antibodies directed against GQ1b [15,16]. Interestingly, the
human oculomotor nerves, which innervate the eye muscles
and are affected in MFS, have a relatively high content of
GQ1b, which could explain their vulnerability to damage
mediated by anti-GQ1b antibodies [15].
Antigen recognition is a determining initial step in the
development of immune responses leading to GBS or MFS.
Sialylation of C. jejuni LOS is an important determinant for the
development of GBS and MFS [17]. Therefore, sialic acid-
binding immunoglobulin-like lectins (Siglecs) expressed on
immune-related cells may play a decisive role in immune
recognition. Siglecs comprise a family of surface exposed
receptors that are involved in sialic-acid-dependent cell-to-cell
interactions and ligand binding [18]. Additionally, Siglecs
function as endocytic receptors in immune recognition of
both bacteria and viruses [19–21].
We recently demonstrated that GBS-related C. jejuni strains
speciﬁcally bind to sialoadhesin (Siglec-1) [22]. Furthermore,
other researchers have shown that C. jejuni strains expressing
disialylated LOS structures can bind to Siglec-7 [23]; however,
a limited number (n = 4) of strains were examined and no
correlation was made with the clinical phenotype.
In this study, we determined the epitope speciﬁcity of
C. jejuni for Siglec-7 binding. We examined a large and unique
collection of C. jejuni strains (n = 29) derived from GBS and
MFS patients, for which detailed information was available on
the ganglioside mimicking structures expressed. In particular,
we investigated the relationship between Siglec-7 binding and
the presence of anti-ganglioside antibodies in patient serum
and the speciﬁc clinical phenotypes. This study demonstrates
that Siglec-7 speciﬁcally recognizes the C. jejuni strains asso-
ciated with oculomotor weakness in GBS or MFS.
Materials and Methods
Bacterial strains and culture conditions
A group of 29 successive and well-characterized C. jejuni
strains isolated from the stools of either GBS or MFS patients
(see Supplementary material, Table S1), three previously
described sialic acid transferase (cst-II) knockout mutants of
GBS-associated strains (GB2Dcst-II, GB11Dcst-II and GB19Dcst-
II) [24,25] and the reference strain NCTC 11168 were used in
this study [22,24,26]. Strains GB13, GB14, GB26 and GB27
were cultured from the diarrhoeal stools of the family
members of two GBS patients after a family outbreak of
C. jejuni enteritis [27] (Table S1). The GBS-related and MFS-
related strains predominantly originate from Dutch patients.
Two strains from the Netherlands Antilles and one Belgian
strain were included. C. jejuni strains were cultured from
stocks held at  80°C and maintained on Colombia blood agar
plates (Becton Dickinson BV, Alphen aan den Rijn, the
Netherlands) supplemented with 10 mg/L vancomycin in a
microaerobic atmosphere at 37°C. Chloramphenicol (20 mg/
L) was added to the Dcst-II mutant strain culture plates. For
each experiment, all strains were freshly cultured for 2 days
on blood agar plates containing only vancomycin. The LOS
outer core structures of most GBS/MFS-associated strains
used in this study have been described previously [10]. The
LOS structures of C. jejuni GB29, GB30 and GB33 were
determined using mass spectrometry analysis, as previously
described [10]. Genotyping by PCR was performed to verify
the LOS classes, as previously described [24].
Serology and diagnosis
Serum samples obtained within 2 weeks of the onset of
weakness and before treatment, were tested for the presence
of IgM and IgG antibodies to the ganglioside GQ1b using a
validated ELISA with predeﬁned cut-off values, as previously
described [28]. The diagnosis of GBS or MFS was made by
specialized neurologists, based on previously described criteria
[29,30].
Preparation of Siglec-7-Fc-conjugate
Chinese hamster ovary (CHO) cells expressing the full
extracellular region of human Siglec-7 fused to recombinant
Fc protein (CHO-Siglec-7-Fc) were generated [31] and Siglec-
7-Fc was produced as previously described [22]. Brieﬂy, CHO-
Siglec-7-Fc cells were cultured in glutamine-free Glasgow
Minimal Essential Medium (Sigma-Aldrich, Zwijndrecht, the
Netherlands) containing 100 lM L-methionine sulphoximine
(Sigma-Aldrich), GS supplement (Sigma-Aldrich), penicillin/
streptomycin and 10% dialysed fetal calf serum (Invitrogen,
Leek, the Netherlands). Once the cells reached 80% conﬂu-
ency, the fetal calf serum concentration was adjusted to 2%
and, eventually, the cells were cultured in X-VIVO-10 serum-
free media (Lonza, Verviers, Belgium) and the medium was
harvested weekly. The concentration of Siglec-7-Fc was
determined using an Fc-speciﬁc ELISA, as previously
described [22].
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Siglec-7-Fc ELISA
Two-day C. jejuni cultures grown on blood agar plates were
harvested, washed and the optical density at 600 nm (OD600)
was adjusted to 0.2 in phosphate-buffered saline (PBS) containing
2 mM MgCl2 (PBS-Mg). After heat inactivation at 56°C for
45 min, 100 lL of each sample was plated in triplicate in 96-well
Maxisorp ELISA plates (NUNC Inc., Uden, the Netherlands).
The plateswere kept openovernight at 37°C to allow the ﬂuid to
evaporate. After washing, the wells were blocked for 1 h using
1%bovine serumalbumin in PBS at 37°C. Simultaneously, 1 mg/L
Siglec-7-Fc conjugate was precomplexed with peroxidase-con-
jugated anti-human IgG (IgG-PO; Sigma-Aldrich) diluted 1/3000
in PBS containing 0.05% normal goat serum for 1 h at room
temperature with shaking. After washing, 100 lL precomplexed
Siglec-7-Fcwas added perwell, the plateswere incubated for 2 h
at room temperature, washed four times with PBS containing
0.05% Tween 20 and developed using 100 lL 3′,3′,5′,5′-tetra-
methylbenzidine substrate (Sigma-Aldrich) per well. After an
appropriate incubation time (5–10 min), the reaction was
stopped by adding 100 lL of 2 M H2SO4 per well and signal
intensity wasmeasured spectrophotometrically at 450 nm using
a 96-well microplate reader (Bio-Rad, Veenendaal, the Nether-
lands). With respect to the Siglec-7 inhibition experiment, equal
amounts (300 ng/well) puriﬁed bovine brain GQ1b (Sigma-
Aldrich) were coated on an ELISA plate and blocked to avoid
non-speciﬁc binding. In parallel, precomplexed Siglec-7-Fc was
incubated for 1 hwith twice the number of bacteria we normally
use in our Siglec-7 ELISA to coat the wells. Siglec-7-bound- or
free bacteria were removed by centrifugation. The supernatant
(i.e. non-adsorbed Siglec-7) was transferred to the GQ1b-
coated plate and binding of Siglec-7 was determined as described
above.
Statistical analysis
Two-tailed t tests and Mann–Whitney U tests were performed
using PRISM software (GraphPad, La Jolla, CA, USA) as
indicated; p  0.05 was considered statistically signiﬁcant.
Results
Recognition of C. jejuni by Siglec-7 is sialic acid-speciﬁc
Although it has been shown that disialylated ganglioside-like
structures expressed on the surface of C. jejuni can bind to
Siglec-7 in a sialic acid-dependent manner, the possibility of
low-afﬁnity Siglec-7 binding to monosialylated structures or
complexes could not be excluded [23]. Therefore, we aimed
to determine the precise requirements of ganglioside-like
structures for Siglec-7 binding.
Sialic acid-speciﬁc Siglec-7 binding was determined using
three C. jejuni strains GB2, GB11 (both GM1a+ GD1a+) and
GB19 (GD1c+), and their sialic acid mutants GB2Dcst-II,
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FIG. 1. Schematic illustration of the ganglioside structures discussed in this study. These structures can be mimicked by the Campylobacter jejuni
outer core lipo-oligosaccharides (LOS). However, instead of the ceramide-bound glucose, the C. jejuni LOS has a heptose, followed by an inner sugar
core, and C. jejuni LOS has a lipid A transmembrane tail instead of a ceramide tail. Disialylated structures with a(2,3/2,8)-linked sialic acid residues are
represented in the left panel; monosialylated structures with a(2,3)-linked sialic acid residues are represented in the right panel. (a) GA1, GA2 and
GA3 (or asialo GM1, -GM2 and -GM3) contain no sialic acids and are considered not to be gangliosides.
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GB11Dcst-II (both GA1+ GA2+ GA3+) and GB19Dcst-II (GA1+;
Fig. 1). Strain GB19 showed high Siglec-7 binding afﬁnity in a
whole cell Siglec-7-Fc ELISA (Fig. 2a). In agreement with reports
that disialylated carbohydrate structures speciﬁcally bind to
Siglec-7 [23,32], GB19 (GD1c+) is disialylated at the terminal
galactose of the oligosaccharide chain. GB19Dcst-II demon-
strated reduced Siglec-7 binding, indicating that the binding was
sialic acid-speciﬁc. Comparable background levels of Siglec-7
binding were observed for the monosialylated strains GB2 and
GB11, and their respective non-sialylated Dcst-II mutants
(Fig. 2a). To address whether Siglec-7 binds a similar epitope
on ganglioside GQ1b, an inhibition ELISA was performed.
Compared with GB19Dcst-II, Siglec-7 binding to GQ1b was
signiﬁcantly (p 0.0005; t test) reduced when strain GB19 was
used for adsorption, demonstrating that strain GB19 inhibits
Siglec-7 binding to GQ1b (see Supplementary material, Fig. S1).
GB19Dcst-II showed a reduction in the signal when compared
with the non-blocking situation. This reduction was similar to
that observed with GB11 and GB11Dcst-II, indicating that this
effect was not dependent on sialic acid.
We concluded that Siglec-7 can bind to the disialylated
GD1c-like structure present on C. jejuni LOS in a sialic acid-
dependent manner; however, Siglec-7 cannot bind monosial-
ylated GM1a-like and GD1a-like structures.
In a large collection of GBS/MFS-associated C. jejuni strains,
only disialylated C. jejuni strains bind Siglec-7
To further study ganglioside mimic-speciﬁc Siglec-7 binding, 25
GBS-related and four MFS-related C. jejuni strains with known
LOS structures, and the reference strain NCTC11168 were
tested in the Siglec-7-Fc ELISA. A clear diversity in Siglec-7
binding was observed, with various strains showing high or low
Siglec-7 binding capacity (Fig. 2b). In particular, strains MF06,
GB19, MF07, GB25, MF20, MF08, GB30, GB16 and GB33
strongly bound Siglec-7. Strikingly, all of these strains have
terminally disialylated LOS structures (Fig. 2b). The GD1c-like
structure is disialylated in strains MF06, GB19, GB25, GB16
and GB33; whereas disialylation is present in the GD3-like
structure of strains MF07 and MF08 (Fig. 1; Table S1).
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FIG. 2. Evaluation of the binding of Siglec-7-Fc to Campylobacter jejuni
strains using an ELISA. The strains were heat-inactivated, coated on
ELISA plates, incubated with precomplexed Siglec-7 conjugate and
visualized using 3′,3′,5′,5′-tetramethylbenzidine substrate. The bars
represent a single experiment that was repeated at least three times,
with means and standard deviations of triplicate measurements. Strains
GB2Dcst-II, GB11Dcst-II and GB19Dcst-II are the non-sialylated Campy-
lobacter sialic acid transferase (cst-II) knockout mutants of the parental
wild-type strains GB2, GB11 and GB19, respectively. White bars, non-/
monosialylated lipo-oligosaccharides (LOS); black bars, disialylated
LOS. (a) Siglec-7 binding to parental wild-type and sialic acid
transferase knockout C. jejuni strains. (b) Siglec-7 binding to GBS-
and MFS-associated C. jejuni strains. *Strain GB19Dcst-II was included
as a reference and it is considered to be a negative control for Siglec-7
binding.
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The exact structures of the ganglioside mimics present on
strain GB30 could not be determined because mass spectrom-
etry analysis yielded a complex proﬁle. However, mass spec-
trometry analysis conﬁrmed the presence of monosialic and
disialic acids in theLOSouter coreof strainGB30. Basedon these
results, it is probable that the GB30 LOS outer core contains
GD3-like structures (M. Gilbert, personal communication).
When the non-sialylated and monosialylated strains (n = 20)
were compared with the disialylated strains (n = 10), we
observed signiﬁcantly higher Siglec-7 binding for the disialylated
strains (p <0.0001; Mann–Whitney U test; Fig. 3a). Binding of
the non-sialylated and monosialylated strains was low and
comparable to the binding of strain GB19Dcst-II, which lacks
sialic acid. Strain GB17 did not strongly bind Siglec-7, despite the
presence of disialylated ganglioside-like structures. It is possible
that this strain contains additional structures that hinder Siglec-
7 binding. Therefore, we concluded that only C. jejuni equipped
with terminally disialylated ganglioside-like structures can bind
to Siglec-7.
Siglec-7 binding correlates with the presence of anti-GQ1b
antibodies in the serum of patients with GBS
We determined whether Siglec-7 binding correlated with the
presence of anti-GQ1b antibodies in the serum of GBS patients.
The strains isolated from patients with a high anti-GQ1b
antibody titre demonstrated signiﬁcantly higher Siglec-7 binding
than the strains isolated from patients who did not have anti-
GQ1b antibodies (p 0.0002; Mann–Whitney U test; Fig. 3b;
Table S1). Seven of the nine strains that showed strong binding to
Siglec-7 (78%) were isolated from GBS/MFS patients expressing
anti-GQ1b antibodies; no patient serumwas available for testing
from the other two strains. Three strains (GB4, GB17 and
GB22) that did not bind Siglec-7were isolated frompatientswith
anti-GQ1b antibodies. Strain GB4 expresses a class E LOS and
therefore does not carry the genes necessary for sialylation,
which is an essential determinant for ganglioside mimicry. We
hypothesize that this strain (GB4) was not involved in triggering
the patient’s immune system and the subsequent development
of GBS. Strain GB17 (GM1b+ GD1c+ GA1+) contains disialy-
lated LOS but did not bind to Siglec-7; however, the patient had
(low) anti-GQ1b antibodies. Strain GB22 (GD1a+ GM1a+) does
not express disialylated LOS; therefore, it probably does not
bind to Siglec-7. In addition to anti-GQ1b antibodies, the patient
fromwhom strain GB22 was isolated also had antibodies against
GM1a (data not shown), suggesting that strain GB22 may
contribute to the induction of anti-GM1a antibodies but perhaps
not anti-GQ1b antibodies.
Campylobacter jejuni Siglec-7 binding is associated with
oculomotor weakness and MFS
As disialylated C. jejuni strains and anti-GQ1b antibodies are
associated with oculomotor weakness [15,33], we determined
whether Siglec-7 binding also correlated with oculomotor
weakness. Strikingly, all of the patients with oculomotor
weakness (7/7; 100%) were infected with C. jejuni strains that
showed a high binding afﬁnity for Siglec-7 (p 0.0002; Mann–
Whitney U test; Fig. 3c; Table S1). Three of these strains were
isolated from GBS patients and four were isolated from MFS
patients. All of the patients with MFS had been infected with
strains that had a high Siglec-7 binding afﬁnity (4/4; 100%). Two
other strains that bound Siglec-7, GB30 and GB33, were
isolated from GBS patients for whom no information on
oculomotor weakness was available.
Discussion
In the present study, we report that sialylated structures on
the surface of C. jejuni can bind to Siglec-7, a receptor of the
siglec family that is expressed on immune cells including dendritic
cells. We demonstrated that the binding of C. jejuni to Siglec-7 is
sialic acid-dependent, as a sialic acid transferase knockout strain
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FIG. 3. Relationship between Siglec-7 binding by Campylobacter jejuni and (a) lipo-oligosaccharide (LOS) sialylation; (b) the presence of anti-GQ1b
antibodies in Guillain–Barre´ syndrome (GBS) and Miller Fisher syndrome (MFS) patient serum and (c) oculomotor weakness in GBS and MFS
patients. Siglec-7 binding was measured using an ELISA. Four individual bacterial strains were cultured from multiple individuals within two separate
families (see Supplementary material, Table S1); data from only one strain isolated from each family are included in (b) and (c). The median values are
indicated by the horizontal line; p values <0.05 were considered statistically signiﬁcant (Mann–Whitney U test).
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E106–E112
E110 Clinical Microbiology and Infection, Volume 19 Number 2, February 2013 CMI
could not bind Siglec-7 whereas the parental wild-type strain
could. Siglec-7 has a preference for binding disialylated sialic acid
conjugates, such as those present in the ganglioside GQ1b [32].
Indeed, only strains expressing disialylated ganglioside-like struc-
tures could bind Siglec-7; speciﬁcally, the GD1c-like or GD3-like
disialylated ganglioside-mimics present in the C. jejuni strain
collection used in this study. Similar to GQ1b, both GD1c and
GD3are disialylated at the terminal galactoseof the carbohydrate
chain. Infection with GD1c-positive or GD3-positive C. jejuni
strains has been previously associatedwith the presence of cross-
reactive anti-GQ1b antibodies in the serum of GBS or MFS
patients [16,33,34]. Upon screening a large panel of GBS-related
and MFS-related C. jejuni strains, we observed an association
between Siglec-7 binding and the presence of anti-GQ1b
antibodies in patient serum. Furthermore, we found that Siglec-
7 selectively recognized the C. jejuni strains that were isolated
fromGBSorMFS patients diagnosedwith oculomotorweakness,
strongly suggesting that the speciﬁc binding of C. jejuni to Siglec-7
is a marker for GBS and MFS with oculomotor weakness.
Our ﬁndings are in concordance with previous studies that
reported that Siglec-7 can interact with terminally disialylated
ganglioside structures, including GD3, GT1b and GQ1b
[32,35]. An interaction of Siglec-7 with C. jejuni strains
expressing disialylated LOS structures was also previously
demonstrated using ELISA and CHO-cell adhesion assays [23];
however, a limited number of strains were tested and the
correlation with clinical phenotypes was not examined.
It has been suggested that the presence of other ganglioside
mimics inﬂuences the interaction with Siglec-7 [23]. Polyviny-
lidene diﬂuoride glycoarray-based experiments revealed that a
1:1 complex of either GM1, GM2, GD1a, GD1b or GT1a with
GD3 attenuated Siglec-7 binding [35]. Therefore, the binding
of Siglec-7 to the GD3-like structure of the strains MF07
(GM2+ GD2+ GD3+) and MF08 (GM2+ GD3+) used in this
study could potentially be affected by the presence of GM2. As
Siglec-7 binding was clearly observed for these strains,
complex attenuation is apparently not a major issue. However,
complex attenuation may explain why strain GB17
(GM1b+ GD1c+ GA1+) did not bind to Siglec-7. It should be
noted that in serum of patient GB17, complex reactivity
against GM1/GD1a, GD1a/GD1b and GD1a/GQ1b was
observed [26]. This suggests that the ganglioside-like epitopes
on GB17 LOS form complexes. The formation of these
complexes might prevent Siglec-7 binding. It is also possible
that the GD1c-like structure was expressed in low levels on
the surface of GB17 under the current culture conditions,
resulting in low Siglec-7 binding.
The consequence of pathogen interactions with Siglec-7 is
largely unknown. Siglec-7 is a member of the CD33-related
Siglecs, which contain immunoreceptor tyrosine-based inhib-
itory motifs (ITIMs) in their cytoplasmic tail. Pathogen
interactions with Siglec-7 could therefore exert an inhibitory
effect on immune activation, as ITIM signalling has been shown
to restrain Siglec internalization via ITIM phosphorylation [36].
However, Siglec-related pathogen uptake has also been
reported [19]. It is possible that cis interaction of Siglec-7
with self-ligands results in an inhibitory response; whereas
pathogen interactions with Siglec-7 overrule this signal,
possibly through activation of co-receptors and cytokine
secretion, or a higher receptor afﬁnity [37]. Evidence for a
Siglec-7-activated immune response was recently demon-
strated, as Siglec-7 interactions resulted in the skewing of
dendritic cells towards T helper type 1 polarization, due to
LOS-mediated OX40 ligand induction [38]. However, the
mechanisms by which this process could eventually lead to an
anti-ganglioside antibody response and result in GBS or MFS
with oculomotor weakness remain to be elucidated.
In conclusion, we demonstrate that oculomotor weakness
in GBS and MFS is associated with C. jejuni strains that bind
Siglec-7. Binding of C. jejuni to Siglec-7 may be an event that
mediates anti-GQ1b antibody activation, leading to oculomo-
tor weakness in patients with GBS or MFS. Identiﬁcation of
C. jejuni on the basis of Siglec-7 binding could be of diagnostic
value for the detection of strains with the potential to induce
neurological symptoms. In cases of C. jejuni infection where a
Siglec-7 binding strain is cultured from faecal samples, antibi-
otic treatment could be prescribed to prevent postinfections
neurological complications. Additional studies are necessary to
identify the occurrence of Siglec-7 binding strains in uncom-
plicated enteritis.
Acknowledgements
We thank Paul Crocker, College of Life Sciences, University of
Dundee, Dundee, UK, for kindly providing the Siglec-7-Fc
producing cells. We thank Michel Gilbert and Jianjun Li, NRC,
Ottawa, Ontario, Canada, for mass spectrometry analysis of
the C. jejuni GB29, GB30 and GB33 LOS.
Transparency Declaration
The authors declare no conﬂicts of interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E106–E112
CMI Heikema et al. Oculomotor weakness-associated C. jejuni strains speciﬁcally bind Siglec-7 E111
Figure S1. Campylobacter jejuni-mediated inhibition of
Siglec-7 binding to ganglioside GQ1b.
Table S1. Guillain–Barre´ syndrome- and Miller Fisher
syndrome-associated Campylobacter jejuni strains used in this
study.
References
1. Hahn AF. Guillain–Barre´ syndrome. Lancet 1998; 352: 635–641.
2. Hughes RA, Cornblath DR. Guillain–Barre´ syndrome. Lancet 2005; 366:
1653–1666.
3. Tam CC, O’Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC.
Guillain–Barre´ syndrome and preceding infection with Campylobacter,
inﬂuenza and Epstein–Barr virus in the general practice research
database. PLoS ONE 2007; 2: e344.
4. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and
treatment of Guillain–Barre´ syndrome. Lancet Neurol 2008; 7: 939–950.
5. Fisher M. An unusual variant of acute idiopathic polyneuritis: syndrome
of ophthalmoplegia, ataxia and areﬂexia. N Engl J Med 1956; 255: 57–65.
6. Funakoshi K, Kuwabara S, Odaka M, Hirata K, Yuki N. Clinical
predictors of mechanical ventilation in Fisher/Guillain–Barre´ overlap
syndrome. J Neurol Neurosurg Psychiatry 2009; 80: 60–64.
7. Rajabally YA, Hassan-Smith G, Notturno F et al. Motor and sensory
conduction failure in overlap of Guillain–Barre´ and Miller Fisher
syndrome: two simultaneous cases. J Neurol Sci 2011; 303: 35–38.
8. Jacobs BC, Rothbarth PH, van der Meche´ FGA et al. The spectrum of
antecedent infections in Guillain–Barre´ syndrome: a case–control
study. Neurology 1998; 51: 1110–1115.
9. Koga M, Gilbert M, Li J et al. Antecedent infections in Fisher syndrome:
a common pathogenesis of molecular mimicry. Neurology 2005; 64:
1605–1611.
10. Godschalk PC, Kuijf ML, Li J et al. Structural characterization of
Campylobacter jejuni lipooligosaccharide outer cores associated with
Guillain–Barre´ and Miller Fisher syndromes. Infect Immun 2007; 75:
1245–1254.
11. Hafer-Macko CE, Sheikh KA, Li CY et al. Immune attack on the
Schwann cell surface in acute inﬂammatory demyelinating polyneurop-
athy. Ann Neurol 1996; 39: 625–635.
12. Yuki N, Susuki K, Koga M et al. Carbohydrate mimicry between human
ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes
Guillain–Barre´ syndrome. Proc Natl Acad Sci USA 2004; 101: 11404–
11409.
13. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid
antibodies. Brain 2002; 125: 2591–2625.
14. Hiraga A, Kuwabara S, Ogawara K et al. Patterns and serial changes in
electrodiagnostic abnormalities of axonal Guillain–Barre´ syndrome.
Neurology 2005; 64: 856–860.
15. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-
GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher
syndrome and Guillain–Barre´ syndrome: clinical and immunohisto-
chemical studies. Neurology 1993; 43: 1911–1917.
16. Ang CW, Laman JD, Willison HJ et al. Structure of Campylobacter jejuni
lipopolysaccharides determines antiganglioside speciﬁcity and clinical
features of Guillain–Barre´ and Miller Fisher patients. Infect Immun 2002;
70: 1202–1208.
17. van Belkum A, van den Braak N, Godschalk P et al. A Campylobacter
jejuni gene associated with immune-mediated neuropathy. Nat Med
2001; 7: 752–753.
18. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune
system. Nat Rev Immunol 2007; 7: 255–266.
19. Jones C, Virji M, Crocker PR. Recognition of sialylated meningococcal
lipopolysaccharide by Siglecs expressed on myeloid cells leads to
enhanced bacterial uptake. Mol Microbiol 2003; 49: 1213–1225.
20. Rempel H, Calosing C, Sun B, Pulliam L. Sialoadhesin expressed on
IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS
ONE 2008; 3: e1967.
21. Vanderheijden N, Delputte PL, Favoreel HW et al. Involvement of
sialoadhesin in entry of porcine reproductive and respiratory syndrome
virus into porcine alveolar macrophages. J Virol 2003; 77: 8207–8215.
22. Heikema AP, Bergman MP, Richards H et al. Characterization of the
speciﬁc interaction between sialoadhesin and sialylated Campylobacter
jejuni lipooligosaccharides. Infect Immun 2010; 78: 3237–3246.
23. Avril T, Wagner ER, Willison HJ, Crocker PR. Sialic acid-binding
immunoglobulin-like lectin 7 mediates selective recognition of sialylat-
ed glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect
Immun 2006; 74: 4133–4141.
24. Godschalk PC, Heikema AP, Gilbert M et al. The crucial role of
Campylobacter jejuni genes in anti-ganglioside antibody induction in
Guillain–Barre´ syndrome. J Clin Invest 2004; 114: 1659–1665.
25. Louwen R, Heikema A, van Belkum A et al. The sialylated lipooligo-
saccharide outer core in Campylobacter jejuni is an important determi-
nant for epithelial cell invasion. Infect Immun 2008; 76: 4431–4438.
26. Kuijf ML, Godschalk PC, Gilbert M et al. Origin of ganglioside complex
antibodies in Guillain–Barre´ syndrome. J Neuroimmunol 2007; 188: 69–
73.
27. Ang CW, van Doorn PA, Endtz HP et al. A case of Guillain–Barre´
syndrome following a family outbreak of Campylobacter jejuni enteritis. J
Neuroimmunol 2000; 111: 229–233.
28. Kuijf ML, van Doorn PA, Tio-Gillen AP et al. Diagnostic value of anti-
GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol
Sci 2005; 239: 37–44.
29. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria
for Guillain–Barre´ syndrome. Ann Neurol 1990; 27: S21–S24.
30. Miller Fisher C. An unusual variant of acute idiopathic polyneuritis
(syndrome of ophthalmoplegia, ataxia and areﬂexia). N Engl J Med 1956;
225: 57–65.
31. Vinson M, van der Merwe PA, Kelm S, May A, Jones EY, Crocker PR.
Characterization of the sialic acid-binding site in sialoadhesin by site-
directed mutagenesis. J Biol Chem 1996; 271: 9267–9272.
32. Rapoport E, Mikhalyov I, Zhang J, Crocker P, Bovin N. Ganglioside
binding pattern of CD33-related Siglecs. Bioorg Med Chem Lett 2003; 13:
675–678.
33. Yuki N. Campylobacter sialyltransferase gene polymorphism directs
clinical features of Guillain–Barre´ syndrome. J Neurochem 2007; 103
(suppl 1): 150–158.
34. Yuki N. Infectious origins of, and molecular mimicry in, Guillain–Barre´
and Fisher syndromes. Lancet Infect Dis 2001; 1: 29–37.
35. Rinaldi S, Brennan KM, Goodyear CS et al. Analysis of lectin binding to
glycolipid complexes using combinatorial glycoarrays. Glycobiology 2009;
19: 789–796.
36. Walter RB, Raden BW, Zeng R, Hausermann P, Bernstein ID, Cooper
JA. ITIM-dependent endocytosis of CD33-related Siglecs: role of
intracellular domain, tyrosine phosphorylation, and the tyrosine
phosphatases, SHP1 and SHP2. J Leukoc Biol 2008; 83: 200–211.
37. Paulson JC, Macauley MS, Kawasaki N. Siglecs as sensors of self in
innate and adaptive immune responses. Ann N Y Acad Sci 2012; 1253:
37–48.
38. Bax M, Kuijf ML, Heikema AP et al. Campylobacter jejuni lipooligosac-
charides modulate dendritic cell-mediated T cell polarization in a sialic
acid linkage-dependent manner. Infect Immun 2011; 79: 2681–2689.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E106–E112
E112 Clinical Microbiology and Infection, Volume 19 Number 2, February 2013 CMI
